Archives
Provisional finding in drug price hikes case
The UK’s competition regulator has made a provisional finding in the longstanding investigation into drug price hikes, and the outcome is damning.
Issues surrounding pharmaceutical competition breaches are numerous and serious. At the end of the day, the consumer in these cases is patients and the NHS; that’s our tax money.
Any infringement of vital competition laws when it comes to medical matters should always lead to significant punishments, and the work of the CMA (Competition and Markets Authority) in this area is incredibly important. The provisional finding in this matter accompanies an admission from one of the companies involved as well.
More time allowed in the supply of groundworks investigation
More time has been allowed for representations to be made in the supply of groundworks investigation that’s currently being undertaken by the UK’s competition regulator.
The CMA (Compensation and Markets Authority) issued their statement of objections back in April 2019 and announced their provisional findings. The CMA confirmed that they suspect there are three suppliers who are engaging in behaviour that may distort competition in the market. Until final determinations are made, these are just allegations at this stage.
Notably, the CMA decided to continue with their investigations, so we assume that they must believe that there is some evidence to support their allegations.
Most favoured nation clauses in price comparison websites sector
As it has been a while since we looked at this one, here’s the latest in the investigation into alleged most favoured nation clauses in the price comparison website sector.
The investigation that’s being carried out by the Competition and Markets Authority (CMA) is over the alleged use of such clauses for price comparison websites in relation to insurance products. The term “most favoured nation” originates from international trade agreements, whereby more favourable trade terms have been used between countries who favour each other more. In terms of competition law, it’s about contractual provisions whereby a seller may provide their best terms specifically to a particular buyer.
Such behaviour can restrict and distort competition, which is why it’s important for the CMA to look into it.
Precast concrete drainage products supply investigation: latest
The CMA (Competition and Markets Authority) has issued an update in the investigation into the supply of precast concrete drainage products.
The civil investigation has been ongoing since 2016 and a number of actions and steps have been taken in the three years since it was commenced.
This month, an important development has been announced which involves fines in the tens of millions for companies who have reportedly been engaging in cartel behaviour for a number of years.
Hydrocortisone tablets competition investigation
Here’s the latest in the hydrocortisone tablets competition investigation that’s being conducted by the Competition and Markets Authority (CMA).
The history of this key study goes way back to October 2017 when the CMA started looking into alleged anti-competitive agreements and alleged abusive conduct. Exactly two years on, a great deal has happened as the CMA looks to ensure that the NHS and patients alike are not being ripped off by vastly wealthy pharmaceutical companies.
As we often say when the investigation involves the healthcare industry, this is a serious and important matter.
Anti-virus software sector investigation latest
Here’s the latest in the important anti-virus software sector investigation that’s being conducted by the CMA (Competition and Markets Authority).
It’s an important one, especially given how prevalent cybersecurity is these days. There have been so many hacks and attacks in recent times that all organisations – both public and private sector – must invest properly to ensure that they’re defended.
But are service providers in the sector offering their vital line of defence in terms that are deemed as fair, and in the spirit of healthy competition? That’s essentially what the CMA wants to find out.
Loyalty penalty investigation: the latest
There has been an update about some of the positive steps that have been taken in the wake of the huge loyalty penalty investigation, often referred to as a “super complaint”.
A “super complaint” is a complaint that’s usually submitted by a consumer body on behalf of a number of people who have the same complaint against sometimes several companies, and sometimes across more than one sector. The loyalty penalty super complaint stemmed from the Citizens Advice Bureau who had raised concerns over customers paying more for goods and services for sticking with the same suppliers.
This one has covered notable areas that include insurance, mortgages, bank accounts, broadband services and mobile services.
Anti-competitive agreements for pharmaceutical drugs: statement of objections issued
In the latest investigation into suspected anti-competitive agreements for pharmaceutical drugs, a statement of objections has been issued by the CMA (Competition and Markets Authority).
The statement was issued last month and relates to a number of pharmaceutical companies who stand accused of participating in anti-competitive behaviour. Whether it’s a case of formal agreements in place, or concerted practices, the issue surrounds the supply of 50mg and 100mg nitrofurantoin capsules in the UK.
This investigation by the CMA into the practices of pharmaceutical firms is one of many that have been ongoing for a number of years. They’re one of the most important areas the CMA needs to safeguard.
Barchester consumer protection case
The Competition and Markets Authority (CMA) is taking action in the Barchester consumer protection case under the pretence that consumer laws may have been broken.
The wider action surrounding care homes in the UK has been going on for over two years now, and we recently reported about the court action launched against Care UK.
Now, the CMA has sent a letter before action to Barchester Healthcare Limited, Barchester Healthcare Homes Limited, Grove Limited and Barchester Holdco (Jersey) Limited; known altogether as ‘Barchester’. It’s alleged that certain fees that have been charged contravene consumer protection laws.
The ongoing Viagogo court case between the Competition and Markets Authority (CMA) and the secondary ticketing website is about to step up.
The CMA are reportedly moving ahead with contempt of court proceedings on the basis that they say Viagogo is still failing to adhere to a court order obtained earlier this year.
This is huge news, and it’s alarming to hear that the CMA considers that the ticketing resellers are still failing to comply with a court order. Following a market sector review, a number of firms changed their behaviours, but it appears that Viagogo isn’t fully complying.